A Study Comparing Valsartan With And Without Hydrochlorothiazide In Patients With Hypertension
Primary Purpose
Hypertension
Status
Completed
Phase
Phase 3
Locations
United States
Study Type
Interventional
Intervention
VALSARTAN, VALSARTAN+HYDROCHLOROTHIAZIDE
Sponsored by

About this trial
This is an interventional treatment trial for Hypertension focused on measuring HYPERTENSION, VALSARTAN
Eligibility Criteria
Inclusion Criteria: SUCCESSFUL COMPLETION OF STUDY CVAH631C2301 - Exclusion Criteria: NONE
Sites / Locations
- Novartis Pharmaceuticals
Outcomes
Primary Outcome Measures
Adverse events and serious adverse events at each study visit for 54 weeks
Secondary Outcome Measures
Change from baseline in diastolic blood pressure from baseline after 54 weeks
Change from baseline in systolic blood pressure from baseline after 54 weeks
Change from baseline in standing diastolic and systolic blood pressure after 54 weeks
Hematology and blood chemistries up to 54 weeks
Physical condition including pregnancy, pulse and weight at each study visit
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00241007
Brief Title
A Study Comparing Valsartan With And Without Hydrochlorothiazide In Patients With Hypertension
Official Title
A Study Comparing Valsartan With And Without Hydrochlorothiazide In Patients With Hypertension
Study Type
Interventional
2. Study Status
Record Verification Date
October 2005
Overall Recruitment Status
Completed
Study Start Date
December 2003 (undefined)
Primary Completion Date
March 2005 (Actual)
Study Completion Date
March 2005 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Novartis
4. Oversight
5. Study Description
Brief Summary
SAFETY EXTENSION STUDY TO THE CORE STUDY CVAH631C2301
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hypertension
Keywords
HYPERTENSION, VALSARTAN
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
Double
Allocation
Randomized
Enrollment
836 (Actual)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
VALSARTAN, VALSARTAN+HYDROCHLOROTHIAZIDE
Primary Outcome Measure Information:
Title
Adverse events and serious adverse events at each study visit for 54 weeks
Secondary Outcome Measure Information:
Title
Change from baseline in diastolic blood pressure from baseline after 54 weeks
Title
Change from baseline in systolic blood pressure from baseline after 54 weeks
Title
Change from baseline in standing diastolic and systolic blood pressure after 54 weeks
Title
Hematology and blood chemistries up to 54 weeks
Title
Physical condition including pregnancy, pulse and weight at each study visit
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
SUCCESSFUL COMPLETION OF STUDY CVAH631C2301
-
Exclusion Criteria:
NONE
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Novartis Pharmaceuticals
Organizational Affiliation
Novartis Pharmaceuticals
Official's Role
Study Chair
Facility Information:
Facility Name
Novartis Pharmaceuticals
City
East Hanover
State/Province
New Jersey
ZIP/Postal Code
07936
Country
United States
12. IPD Sharing Statement
Learn more about this trial
A Study Comparing Valsartan With And Without Hydrochlorothiazide In Patients With Hypertension
We'll reach out to this number within 24 hrs